Sir Gregory Winter, CBE, FRS, FMedSci, HonFRCP
Gregory is a member of the Medical Research Council’s Laboratory of Molecular Biology (LMB) in Cambridge, and a Fellow of Trinity College Cambridge. He has served LMB as a Head of Division, Deputy Director and Acting Director. His scientific career has almost entirely been based in Cambridge where his work included protein sequencing (aminoacyl tRNA synthetases) and nucleic acid sequencing (influenza virus). He later developed technologies for making humanised antibodies (by grafting hypervariable regions from rodent antibodies to human antibodies) and also for making human antibodies in bacteria (by use of antibody repertories and phage display technologies). Most of the therapeutic antibodies on the market were developed using methods devised by him. He was a Founder and Director of Cambridge Antibody Technology (acquired by AstraZeneca), a Founder and Director of Domantis (acquired by GSK) and more recently a Founder and Director of Bicycle Therapeutics. Sir Gregory has received numerous international prizes and awards, and in 2004 was knighted for services to Molecular Biology.
Professor Terence Rabbitts FRS, FMedSci
Terence Howard Rabbitts FRS FMedSci (born 17 June 1946) is currently Professor of Molecular Biology at the University of Oxford. Terence worked in Cambridge from 1973-2006 in the MRC Laboratory of Molecular Biology where he was head of the Division of Protein & Nucleic Acid Chemistry until 2002. He moved to become Director of the Leeds Institute of Molecular Medicine (from 2006 to 2010). He is a Member of the European Molecular Biology Organization (EMBO); a Fellow of the Royal Society (FRS); and a Founder Fellow of the Academy of Medical Sciences (FMedSci).
His scientific work includes pioneering the method of cDNA cloning, mapping human antibody genes, methods for chimaeric antibody production and single domains for blocking protein interactions inside cells. He defined the linkage of antibody and T cell receptor genes with cancer-specific chromosomal translocations, identified new families of oncogenes (such as the LMO2 and HOX11 families) and identified a first gene fusion in a solid tumor (FUS-CHOP). He developed the first gene fusion knock-in and also methods for creating chromosomal translocations de novo.
He has considerable corporate biotechnology experience as chairman of the SAB of Cambridge Antibody Technology and Quadrant Healthcare until their respective IPOs; and a member of the Domantis SAB until the company’s acquisition by GSK. He is currently Chairman of the SAB of Kymab and is a member of the SAB of Oryzon Genomics and of DiThera.
Professor Francesco Di Virgilio
Professor Francesco Di Virgilio is Professor of Clinical Pathology, University of Ferrara, Head of the Postgraduate School in Clinical Pathology and of the PhD School in Molecular Medicine and Pharmacology. He has published over 230 scientific papers, of which over 200 on purinergic receptor signaling, and his corporate experience includes being on the Scientific Advisory Board of Duska Therapeutics Inc and Affectis Pharmaceuticals AG.
He obtained a Medical Degree (MD) from the University of Padova. In 1982-3 he was Honorary Research Assistant at the University College London and in 1986-7 a Visiting Fellow, Department of Physiology and Cellular Biophysics, Columbia University, New York, before becoming Associate Professor of Molecular Pathology at the University of Padova in 1988, and Professor of General Pathology at the University of Ferrara in 1992. He was Chairman of the Center of Excellence for the Study of Inflammation (2001-2010), and Deputy-Rector for Research and Technology Transfer of the University of Ferrara (2011-2015). He is a member of the Faculty of 1000, Cell Biology Section, and an Academic Member of European Academy of Tumor Immunology.